The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CML 2022 | Immune dysregulation and clonal hematopoiesis in MDS
Toshio Kitamura, MD, PhD, The University of Tokyo, Tokyo, Japan, comments on immune dysregulation and clonal hematopoiesis (CH) in myelodysplastic syndromes (MDS), discussing the impact epigenetic mutations in hematopoietic stem cells (HSCs) can have on T cells and tumor immunity. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisor for Rigel
